Early detection of hepatocellular carcinoma by Hyperpolarized [1-13C]pyruvate MRI

Aarhus Universitet0 个研究点目标入组 46 人开始时间: 2024年7月8日最近更新: 2024年8月21日

适应症

试验速览

暂无简介。

•Aged 18 – 85 years. The age and gender of the healthy controls of the main study will be matched to the participating patients., -Pre-menopausal women must be confirmed non-pregnant by an onsite test, •HCC group: -Diagnosed HCC larger than 10 mm confirmed by standard MRI, CT or confirmed by tumour biopsy. -Subgroup 1: Not elected for liver surgery -Subgroup 2: Elected for liver surgery, •Small tumor group: -One or more small lesions in the liver requiring 2 years of repeated follow-up as per the EASL guideline. Could be in a liver with a confirmed HCC.

•-Chronic kidney disease, •Contraindications for MRI with contrast:, •Competing systemic disease (hypertension, dyslipidemia, diabetes etc. allowed), •Hepatic encephalopathy = grade 2., •Stents or other devices implanted close to the liver that may cause imaging artefacts, •Allergy to pyruvate, -Patients with tumors must have eGFR > 30 ml/min/1.73m2, -Significant cardiac disease (as left ventricular outflow obstruction or heart failure), -Significant obstructive lung disease or severe asthma, -Pacemaker, neurostimulator or cholera implant, -Metal foreign bodies such as fragments and irremovable piercings, -Unsafe medical implants (safety of heart valves, hips and the like must be confirmed), -Largest circumference including arms > 160 cm, -Claustrophobia

发起方